Electrocardiographic Markers of Appropriate Implantable Cardioverter-Defibrillator Therapy in Young People with Congenital Heart Diseases

被引:5
|
作者
Benitez Ramos, Dunia Barbara [1 ]
Cabrera Ortega, Michel [2 ]
Castro Hevia, Jesus [3 ]
Dorantes Sanchez, Margarita [3 ]
Aleman Fernandez, Ailema Amelia [3 ]
Castaneda Chirino, Osmin [3 ]
Cruz Cardentey, Marlenis [3 ]
Martinez Lopez, Frank [3 ]
Falcon Rodriguez, Roylan [3 ]
机构
[1] Cardioctr Pediat William Soler, Dept Pediat Cardiol, San Francisco E-100 & Perla, Havana, Cuba
[2] Cardioctr Pediat William Soler, Sect Arrhythmia & Cardiac Pacing, 100 & Perla, Havana, Cuba
[3] Inst Cardiol & Cirugia Cardiovasc, Serv Arrhythmia & Cardiac Pacing, 17 & Paseo,Plaza Revoluc, Havana, Cuba
关键词
Electrocardiographic markers; Implantable cardioverter-defibrillator; Appropriate shocks; Congenital heart disease; FRAGMENTED QRS COMPLEX; SUDDEN CARDIAC DEATH; TORSADE-DE-POINTES; HIGH-RISK PATIENTS; LONG-QT SYNDROME; QUALITY-OF-LIFE; HYPERTROPHIC CARDIOMYOPATHY; T-WAVE; VENTRICULAR-TACHYCARDIA; REPAIRED TETRALOGY;
D O I
10.1007/s00246-017-1711-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Implantable cardioverter-defibrillators (ICDs) are increasingly utilized in patients with congenital heart disease (CHD). Prediction of the occurrence of shocks is important if improved patient selection is desired. The electrocardiogram (ECG) has been the first-line tool predicting the risk of sudden death, but data in CHD patients are lacking. We aim to evaluate the predictive value of electrocardiographic markers of appropriate therapy of ICD in young people with CHD. We conducted a prospective, longitudinal study, in twenty-six CHD patients (mean age 24.7 +/- 5.3 years) who underwent first ICD implantation. Forty-two age- and diagnosis-matched controls were recruited. Twelve-lead ECG and 24 h Holter analysis were performed during a mean follow-up of 38.9 months. Data included heart rate, heart rate variability, QRS duration (QRSd), QTc interval and its dispersion, Tpeak-Tend (Tp-Te) interval and its dispersion, presence of fragmented QRS (fQRS), T wave alternans, atrial arrhythmias, and non-sustained ventricular tachycardia. Implant indication was primary prevention in ten cases (38.5%) and secondary prevention in 16 (61.5%). Overall, 17 subjects (65.3%) received at least one appropriate and effective ICD discharge. fQRS was present in 64.7% of cases with ICD therapy compared with patients without events or controls (p < 0.0001). Tp-e and Tp-e dispersion were significantly prolonged in patients with recurrences (113.5 and 37.2 ms) versus patients without ICD discharge (89.6 and 24.1 ms) or controls (72.4 and 19.3 ms) (p < 0.0001 and p < 0.0001, respectively). On univariate Cox regression analysis QRSd (hazard ratio: 1.19 per ms, p = 0.003), QTc dispersion (hazard ratio: 1.57 per ms, p = 0.002), fQRS (hazard ratio: 3.58 p < 0.0001), Tp-e (hazard ratio: 2.27 per ms, p < 0.0001), and Tp-e dispersion (hazard ratio: 4.15 per ms, p < 0.0001), emerged as strong predictors of outcome. On multivariate Cox analysis fQRS, Tp-e and Tp-e dispersion remained in the model. The presence of fQRS, and both Tp-e and Tp-e dispersion are useful ECG tools in daily clinical practice to identify CHD patients at risk for appropriate ICD therapy.
引用
收藏
页码:1663 / 1671
页数:9
相关论文
共 50 条
  • [41] Implantable cardioverter-defibrillator therapy of short QT syndrome is associated with an inherent risk of inappropiate implantable cardioverter-defibrillator discharges
    Schimpf, R
    Wolpert, C
    Bianchi, F
    Giustetto, C
    Bauersfeld, U
    Gaita, F
    Borggrefe, M
    EUROPEAN HEART JOURNAL, 2004, 25 : 28 - 28
  • [42] Implantable cardioverter-defibrillator treatment and resynchronisation in heart failure
    Linde, C
    HEART, 2004, 90 (02) : 231 - 234
  • [43] Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure
    Bardy, GH
    Lee, KL
    Mark, DB
    Poole, JE
    Packer, DL
    Boineau, R
    Domanski, M
    Troutman, C
    Anderson, J
    Johnson, G
    McNulty, SE
    Clapp-Channing, N
    Davidson-Ray, LD
    Fraulo, ES
    Fishbein, DP
    Luceri, RM
    Ip, JH
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (03): : 225 - 237
  • [44] Potential benefit from implantable cardioverter-defibrillator therapy in children and young adolescents
    Gradaus, R
    Wollmann, C
    Castrucci, M
    Koebe, J
    Hammel, D
    Kotthoff, S
    Block, M
    Breithardt, G
    Boecker, D
    CIRCULATION, 2002, 106 (19) : 408 - 408
  • [45] Potential benefit from implantable cardioverter-defibrillator therapy in children and young adolescents
    Gradaus, R
    Wollmann, C
    Köbe, J
    Hammel, D
    Kotthoff, S
    Block, M
    Breithardt, G
    Böcker, D
    HEART, 2004, 90 (03) : 328 - 329
  • [46] Implantable Cardioverter-Defibrillator Therapy in the Contemporary Era of Heart Failure Therapeutics COMMENT
    Chatterjee, Neal A.
    Levy, Wayne C.
    JACC-CLINICAL ELECTROPHYSIOLOGY, 2022, 8 (08) : 1031 - 1033
  • [47] IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR THERAPY IN PATIENTS WHO HAVE GENETIC HEART DISEASE
    McGriff, Deepa
    Protas, Matthew
    Katsiyiannis, William
    Kallinen, Linda
    Hauser, Robert
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 61 (10) : E360 - E360
  • [48] Implications of implantable cardioverter defibrillator therapy in congenital heart disease and pediatrics
    Alexander, ME
    Cecchin, F
    Walsh, EP
    Triedman, JK
    Bevilacqua, LM
    Berul, CI
    JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2004, 15 (01) : 72 - 76
  • [49] Heart failure patients unresponsive to implantable cardioverter-defibrillator therapy: a neglected problem
    Disertori, Marcello
    Mase, Michela
    Rigoni, Marta
    Nollo, Giandomenico
    Ravelli, Flavia
    EUROPEAN JOURNAL OF HEART FAILURE, 2019, 21 (12) : 1507 - 1509
  • [50] Implantable cardioverter-defibrillator therapy after myocardial infarction
    Steinbeck, G
    Andresen, D
    Senges, J
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (10): : 1039 - 1040